<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The recent identification of TGFBR2 mutations in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> II (MFSII) [Mizuguchi et al </plain></SENT>
<SENT sid="1" pm="."><plain>(2004); Nat Genet 36:855-860] and of TGFBR1 and TGFBR2 mutations in Loeys-Dietz <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> syndrome (LDS) [Loeys et al </plain></SENT>
<SENT sid="2" pm="."><plain>(2005); Nat Genet 37:275-281] [OMIM 609192] has provided direct evidence of abnormal signaling in transforming growth factors beta (TGF-beta) in the pathogenesis of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In light of this, we describe the phenotypes and genotypes of five individuals </plain></SENT>
<SENT sid="4" pm="."><plain>Patient 1 had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and abnormal cranial dura </plain></SENT>
<SENT sid="5" pm="."><plain>Patient 2 had severe early <z:hpo ids='HP_0003674'>onset</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and an abnormal skull </plain></SENT>
<SENT sid="6" pm="."><plain>Patients 3 and 4 had probable Furlong syndrome (FS) </plain></SENT>
<SENT sid="7" pm="."><plain>Patient 5 had marfanoid (MD) features, <z:hpo ids='HP_0001249'>mental retardation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>), and a deletion of chromosome 15q21.1q21.3 </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had a condition within the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, MD-<z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> (CS) or MD-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> spectrum </plain></SENT>
<SENT sid="9" pm="."><plain>The names of these entities may become redundant, and instead, come to be considered within the spectrum of TGF-beta signaling pathway disorders </plain></SENT>
<SENT sid="10" pm="."><plain>Two recurrent heterozygous FBN1 mutations were found in Patients 1 and 2, and an identical novel heterozygous de novo TGFBR1 mutation was found in Patients 3 and 4, in whom altered fibrillin-1 processing was demonstrated previously [Milewicz et al </plain></SENT>
<SENT sid="11" pm="."><plain>(2000); Am J Hum Genet 67:279] </plain></SENT>
<SENT sid="12" pm="."><plain>A heterozygous FBN1 deletion was found in Patient 5 </plain></SENT>
<SENT sid="13" pm="."><plain>These findings support the notion that perturbation of extracellular matrix homeostasis and/or remodeling caused by abnormal TGF-beta signaling is the core pathogenetic mechanism in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and related entities including the MD-CS syndromes </plain></SENT>
</text></document>